These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 299220)

  • 1. [Specific immunotherapy in metastasizing breast cancer combined with chemotherapy. A prospective randomized study].
    Graninger W; Bettelheim P; Jakesz R; Rainer H; Moser K; Mörz R; Miksche M
    Acta Med Austriaca Suppl; 1979; 6():322-4. PubMed ID: 299220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Supportive therapy with xenogenous peptides in patients with metastatic breast cancer undergoing aggressive chemotherapy (modified AC-protocol): a prospective, randomized double-blind study].
    Lange OF
    Onkologie; 1987 Jun; 10(3 Suppl):40-3. PubMed ID: 3309762
    [No Abstract]   [Full Text] [Related]  

  • 3. [Carcinoma of the breast. Immunobiology and immunotherapy].
    Sega E; Castelli M; Sega FM
    Minerva Ginecol; 1982 Nov; 34(11):981-4. PubMed ID: 7155428
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized clinical trials in breast cancer: a tabular summary. Part 1: Primary breast cancer.
    Conrad B; Kieser R
    Arch Geschwulstforsch; 1986; 56(3):211-36. PubMed ID: 3524501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of chemotherapy in adjuvant treatment of breast cancer: modulation of the immune status].
    Fargeot P; Guerrin J
    Bull Cancer; 1984; 71(4):346-53. PubMed ID: 6388673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Problems in internal medicine therapy of breast cancer].
    Reinhardt U; Wolf H; Müller C
    Z Gesamte Inn Med; 1987 Mar; 42(5):134-7. PubMed ID: 3590890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
    Kimura H; Yamaguchi Y
    Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cellular immunotherapy in advanced carcinoma of the breast by means of tumour antigen-specific autologous T-memory bone marrow cells as a phase I study].
    Schütz F
    Zentralbl Gynakol; 2004 Dec; 126(6):365-7. PubMed ID: 15570551
    [No Abstract]   [Full Text] [Related]  

  • 9. [Preliminary clinical results of antineoplastic immunotherapy associated with cytostatic treatments].
    Pederzini A; Guerra GP
    Boll Ist Sieroter Milan; 1971; 50(4):268-77. PubMed ID: 5163494
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospective randomized clinical trial: protoadjuvant chemotherapy vs. protoadjuvant radiotherapy in breast cancer stages T3/4, N+/-, M0.
    Rainer H
    Wien Med Wochenschr; 1985 Dec; 135(23-24):599-602. PubMed ID: 3913160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunological problems in radiotherapy and adjuvant cytostatic chemotherapy of breast cancer].
    Pusztai-Markos Z
    Fortschr Med; 1979 Mar; 97(11):487-93. PubMed ID: 369967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
    Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS
    Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer immunotherapy.
    Zhou J; Zhong Y
    Cell Mol Immunol; 2004 Aug; 1(4):247-55. PubMed ID: 16225767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemo-immunotherapy with levamisole in metastatic breast carcinoma: a controlled clinical trial.
    Paterson AH; Edwards AM; Nutting M; Schinnour D; Takats L; McClelland A
    Cancer Clin Trials; 1980; 3(1):5-10. PubMed ID: 6993035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
    J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inflammatory breast carcinoma treated with a combination of chemotherapy and radiation therapy. Results of a randomized trial studying the therapeutic role of an immunotherapy with BCG (author's transl)].
    Pouillart P; Palangie T; Jouve M; Garcia-Giralt E; Vilcoq JR; Bataini JP; Calle R; Fenton J; Mathieu G; Rousseau J; Asselain B
    Bull Cancer; 1981; 68(2):171-86. PubMed ID: 7016224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
    Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
    Br J Cancer; 2001 Apr; 84(7):915-9. PubMed ID: 11286471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer of the breast. Chemotherapy.
    Kardinal CG
    Major Probl Clin Surg; 1979; 5():405-47. PubMed ID: 379453
    [No Abstract]   [Full Text] [Related]  

  • 19. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
    Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
    Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.